InvestorsHub Logo
Followers 495
Posts 32125
Boards Moderated 0
Alias Born 03/12/2014

Re: None

Friday, 05/17/2024 10:08:21 AM

Friday, May 17, 2024 10:08:21 AM

Post# of 647605
NKGN

keep an eye on this ticker next 2 weeks

Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01, which has demonstrated enhanced cytotoxicity and activating receptor expression for the treatment of neurodegenerative diseases and solid tumors, at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) to be held in Nanjing, China, from May 22–24, 2024.

online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

ePublication Details:

Title: Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.